Loading...
XNAS
XXII
Market cap1mUSD
Jul 24, Last price  
4.27USD
1D
-8.17%
1Q
-87.14%
Jan 2017
-100.00%
IPO
-100.00%
Name

22nd Century Group Inc

Chart & performance

D1W1MN
XNAS:XXII chart
P/E
—
P/S
0.21
EPS
—
Div yield, %
—
Shrs. gr., 5y
-22.53%
Rev. gr., 5y
-24.17%
Revenues
7m
-40.65%
000001,012,14118,7757,278,383528,9918,521,99812,279,97916,600,24426,426,34725,833,00028,111,00030,948,00040,501,00032,204,00011,878,0007,049,000
Net income
-5m
L-66.67%
-59,786-29,672-82,146-55,469-89,933-1,353,903-6,735,281-26,153,158-15,595,358-11,031,931-11,581,430-13,029,117-7,966,911-26,558,000-19,711,000-32,609,000-59,801,000-140,775,000-15,164,000-5,054,000
CFO
-8m
L-46.16%
-43,186-33,547-42,451-87,591-32,004-3,449,430-1,764,4453,855,834-6,582,730-7,321,811-9,887,580-12,068,383-17,844,266-14,588,000-15,621,000-22,839,000-51,714,000-54,987,000-14,345,000-7,723,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
URL
https://www.xxiicentury.com/
IPO date
Oct 17, 2006
Employees
198
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT